 UPPSALA, Sweden, July 1, 2021 PRNewswire -- Orexo AB publ., STO:ORX OTCQX:ORXOY, today announces the enrollment of the first participant in the pivotal study of digital therapeutic modiaTM, in combination with sublingual buprenorphinenaloxone, as part of a clinician-supervised medication-assisted treatment program for the treatment of opioid use disorder OUD. 